Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032277 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 634
- Enrollment target
NCT02032277 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 634 participants.
The verdict
NCT02032277, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 634 participants
- Enrollment target
Study Summary
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- DRUG Placebo
- DRUG Doxorubicin
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 634 participants |
| Start Date | 2014-04-02 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02032277
The ClinicalTrials.gov registry entry for NCT02032277 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 634 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02032277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02032277 about?
NCT02032277 is a clinical study titled "A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer". This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
What is the current status of trial NCT02032277?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 634 participants. The study started on 2014-04-02. Estimated completion is 2020-11-12.
What interventions are being tested in trial NCT02032277?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Placebo (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02032277?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.